Velcade Related Published Studies
Well-designed clinical trials related to Velcade (Bortezomib)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. [2008.08.28]
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. [2008.05.10]
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. [2008.04]
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. [2007.09.01]
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [2007.03.15]
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. [2006.09.01]
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. [2006.07]
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. [2006.02]
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [2005.06.16]
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. [2004.10]
Well-designed clinical trials possibly related to Velcade (Bortezomib)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. [2008.10.15]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.09]
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. [2008.07]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.06.20]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. [2008.05.27]
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. [2007.11.15]
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. [2007.04.01]
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. [2005.10]
Other research related to Velcade (Bortezomib)
Consolidation Therapy with Bortezomib/Lenalidomide/ Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. [2008.10]
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. [2008.10]
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. [2008.09.15]
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. [2008.09.02]
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. [2008.09.01]
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. [2008.09]
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. [2008.08]
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. [2008.07.31]
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. [2008.07.15]
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. [2008.07.01]
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. [2008.07.01]
Bortezomib in the front-line treatment of multiple myeloma. [2008.07]
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. [2008.07]
Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. [2008.07]
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. [2008.06.15]
[Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma] [2008.06]
The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model. [2008.06]
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. [2008.06]
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. [2008.06]
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. [2008.05.07]
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. [2008.05.06]
Expanding role of bortezomib in multiple myeloma: nursing implications. [2008.05]
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). [2008.05]
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. [2008.05]
[Aggravated post-herpetic neuralgia due to bortezomib] [2008.05]
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. [2008.04.24]
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. [2008.04.01]
Bortezomib in mantle cell lymphoma. [2008.04]
[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients.] [2008.04]
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. [2008.04]
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. [2008.03.08]
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. [2008.03.01]
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. [2008.03]
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. [2008.03]
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. [2008.02.01]
Position statement on the use of bortezomib in multiple myeloma. [2008.02]
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. [2008.02]
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment. [2008.02]
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. [2008.02]
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. [2008.01.21]
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. [2008.01]
Bortezomib-induced skin eruption. [2008]
Bortezomib as a therapeutic candidate for neuroblastoma. [2008]
The role of bortezomib in the treatment of lymphoma. [2007.12]
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. [2007.12]
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. [2007.12]
Bortezomib in multiple myeloma. [2007.12]
[Role of bortezomib in the treatment of multiple myeloma] [2007.12]
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. [2007.12]
Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature. [2007.12]
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. [2007.11]
Bortezomib inhibits osteoclast activity in patients with multiple myeloma. [2007.11]
Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma. [2007.10.01]
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. [2007.10.01]
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. [2007.10]
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. [2007.10]
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice] [2007.10]
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. [2007.10]
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. [2007.09.20]
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. [2007.09.15]
Bortezomib for the treatment of mantle cell lymphoma. [2007.09.15]
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. [2007.09.01]
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. [2007.09]
Incorporating bortezomib into the treatment of lung cancer. [2007.08.01]
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. [2007.08]
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. [2007.08]
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. [2007.08]
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. [2007.08]
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. [2007.08]
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. [2007.08]
Community experience with bortezomib in patients with multiple myeloma. [2007.07]
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. [2007.07]
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. [2007.07]
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. [2007.06.15]
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. [2007.06.02]
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. [2007.06.01]
Efficacy and safety of bortezomib in patients with plasma cell leukemia. [2007.06.01]
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. [2007.06.01]
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. [2007.06]
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. [2007.04.20]
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. [2007.04.19]
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. [2007.04.15]
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. [2007.04]
|
